310 related articles for article (PubMed ID: 26477577)
1. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
Chiou TJ; Chang YF; Wang MC; Kao CW; Lin HY; Chen TY; Hsueh EJ; Lan YJ; Sung YC; Lin SF; Bai LY; Chen CG
Transl Res; 2015 Dec; 166(6):750-761.e4. PubMed ID: 26477577
[TBL] [Abstract][Full Text] [Related]
2. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
4. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
Haselboeck J; Kaider A; Pabinger I; Panzer S
Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
Cook L; Cooper N
Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
8. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
Psaila B; Bussel JB; Linden MD; Babula B; Li Y; Barnard MR; Tate C; Mathur K; Frelinger AL; Michelson AD
Blood; 2012 Apr; 119(17):4066-72. PubMed ID: 22294727
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
Burness CB; Keating GM; Garnock-Jones KP
Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
12. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience.
Çekdemir D; Güvenç S; Özdemirkıran F; Eser A; Toptaş T; Özkocaman V; Haydaroğlu Şahin H; Ermiş Turak E; Esen R; Cömert M; Sadri S; Aslaner M; Uncu Ulu B; Karakuş A; Selim Bapur D; Alacacıoğlu İ; Aydın D; Tekinalp A; Namdaroğlu S; Ceran F; Tarkun P; Kiper D; Çetiner M; Yenerel M; Demir AM; Yılmaz G; Terzi H; Atilla E; Malkan ÜY; Acar K; Öztürk E; Tombak A; Sunu C; Salim O; Alayvaz N; Sayan Ö; Ozan Ü; Ayer M; Gökgöz Z; Andıç N; Kızılkılıç E; Noyan F; Özen M; Pepedil Tanrıkulu F; Alanoğlu G; Özkan HA; Aslan V; Çetin G; Akyol Erikçi A; Deveci B; Ersoy Dursun F; Dermenci H; Aytan P; Gündüz M; Karakuş V; Özlü C; Demircioğlu S; Akay Yanar OM; Özatlı D; Ündar L; Tiftik EN; Türköz Sucak AG; Haznedaroğlu İ; Özcan M; Şencan M; Tombuloğlu M; Özet G; Bilgir O; Turgut B; Özcan MA; Payzın KB; Sönmez M; Ayyıldız O; Dal MS; Ertop Ş; Turgut M; Soysal T; Kaya E; Ünal A; Pehlivan M; Atagündüz I; Tuğlular Fıratlı T; Saydam G; Diz Küçükkaya R
Turk J Haematol; 2019 Nov; 36(4):230-237. PubMed ID: 31327186
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Panzer S
Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
[TBL] [Abstract][Full Text] [Related]
17. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.
Khelif A; Saleh MN; Salama A; Portella MDSO; Duh MS; Ivanova J; Grotzinger K; Roy AN; Bussel JB
Am J Hematol; 2019 Feb; 94(2):200-208. PubMed ID: 30417939
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.
Tarantino MD; Fogarty P; Mayer B; Vasey SY; Brainsky A
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):284-96. PubMed ID: 23492914
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
20. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
